摘要
目的评价双歧杆菌三联活菌联合黄连素治疗慢性腹泻的临床疗效和复发率。方法将120例慢性腹泻患者随机分为应用双歧杆菌三联活菌联合黄连素治疗的观察组、应用左氧氟沙星联合黄连素治疗的对照组,观察两组治疗3周后的疗效及1年复发率,并进行比较。结果观察组总有效率为96.7%,对照组总有效率为78.3%,观察组总有效率明显优于对照组(P<0.05);观察组1年复发率为25.9%,对照组1年复发率为42.6%,差异有统计学意义(P<0.05);两组患者均未发现明显不良反应。结论双歧杆菌三联活菌联合黄连素治疗慢性腹泻安全、有效,复发率低。
Objective To observe the clinical efficacy of berberine Chapeifeikang combination treatment of chronic diarrhea and recurrence rate.Methods 120 patients with chronic diarrhea were randomly divided into observation group Triple viable bifidobacterium joint berberine,Berberine levofloxacin combined control group,60 cases in each group,the last three weeks of treatment,efficacy and recurrence rates after one year,and for comparison.Results The study group triple viable bifidobacterium berberine combined total efficiency of 96.7%,levofloxacin berberine combined total efficiency of the control group was 78.3%,the total efficiency of the observation group than the control group（P〈0.05）;1-year recurrence rate in the observation group of 25.9%,1-year recurrence rate of 42.6% in the control group,the difference was statistically significant（P〈0.05）;groups of patients found no significant adverse reactions.Conclusion Triple viable bifidobacterium berberine combined treatment of chronic diarrhea safe,effective, low recurrence rate,worthy of clinical use.
出处
《中国药物经济学》
2014年第5期33-35,共3页
China Journal of Pharmaceutical Economics
关键词
黄连素
双歧杆菌三联活菌
慢性腹泻
Berberine
Triple viable bifidobacterium
Chronic diarrhea
